## **Electronic Supplementary Material 1**

Table E1. Normality test for baseline and endpoint variables of resting SBP, DBP, HR, HGS, saliva NO<sub>2</sub>,NO<sub>3</sub> and urine NO<sub>3</sub>, Vitamin C.

HR, HGS, Saliva NO <sub>2</sub> ,NC	Shapiro-Wilk		
Variables	Statistic	df	Sig.
Resting SBP - Baseline	.904	10	.241
Resting DBP - Baseline	.955	10	.726
Resting HR - Baseline	.944	10	.594
HGS - Baseline	.800	10	.051
Saliva NO <sub>2</sub> - Baseline	.845	10	.061
Saliva NO <sub>3</sub> - Baseline	.863	10	.082
Urine $NO_3^-$ - Baseline	.844	10	.050
Vitamin C Urine - Baseline	.625	10	<.001
LOG 10 Vitamin C Urine - Baseline	.945	10	.606
8-isoprostanes - Endpoint	.834	10	.133
Saliva NO <sub>2</sub> by strip - Endpoint	.744	10	.223
Resting SBP - Endpoint	.954	10	.713
Resetting DBP - Endpoint	.935	10	.504
Resting HR - Endpoint	.822	10	.067
HGS - Endpoint	.934	10	.071
Saliva NO <sub>2</sub> - Endpoint	.887	10	.156
Saliva $NO_3^-$ - Endpoint	.863	10	.083
Urine $NO_3^-$ - Endpoint	.877	10	.119
Vitamin C Urine - Endpoint	.831	10	.094
8-Isoprostanes - Endpoint	.734	10	.053
Saliva NO <sub>2</sub> by strip - Endpoint	.644	10	.063
Day 0 SBP	.976	10	.941
Day 1 SBP	.865	10	.087
Day 2 SBP	.963	10	.821
Day 3 SBP	.918	10	.342
Day 0 DBP	.847	10	.053
Day 1 DBP	.926	10	.412
Day 2 DBP	.976	10	.938
Day 3 DBP	.942	10	.577

Keys: SBP: systolic blood pressure; DBP: diastolic blood pressure; HR: heart rate; HGS, hand-grip strength.  $NO_2^-$ : nitrite;  $NO_3^-$ : nitrate, LOG; logarithm

Table E2. Normality test for baseline Finapres variables				
Variables	Shapiro-Wilk			
	Statistic	df	Sig.	
Resting systolic BP (mmHg)	.947	10	.631	
Resting diastolic BP (mmHg)	.852	10	.061	
Resting HR (bpm)	.830	10	.083	
Resting SV(ml)	.962	10	.803	
Resting CO (ml/min)	.949	10	.657	
Resting TPR (mm Hg·min/L)	.943	10	.584	
HG Systolic BP (mmHg)	.946	10	.618	
HG Diastolic BP (mmHg)	.756	10	.084	
HG HR (beats/min)	.912	10	.299	
HG SV (ml)	.923	10	.383	
HG CO (ml/min)	.935	10	.500	
HG TPR (mm Hg·min/L)	.900	10	.219	
Recovery Systolic BP (mmHg)	.848	10	.055	
Recovery Diastolic BP (mmHg)	.817	10	.093	
Recovery HR ( beats/min )	.929	10	.441	
Recovery SV (ml)	.920	10	.354	
Recovery CO (ml/min)	.872	10	.105	
Recovery TPR (mm Hg·min/L)	.672	10	.541	
Resting systolic BP (mmHg)	.975	10	.931	
Resting diastolic BP(mmHg)	.948	10	.645	
Resting HR(bpm)	.952	10	.688	
Resting SV(ml)	.904	10	.240	
Resting CO (ml/min)	.959	10	.773	
Resting TPR (mm Hg·min/L)	.953	10	.708	
HG Systolic BP (mmHg)	.850	10	.058	
HG Diastolic BP (mmHg)	.882	10	.137	
HG HR ( beats/min)	.893	10	.183	
HG SV (ml)	.900	10	.222	
HG CO (ml/min)	.981	10	.970	
HG TPR (mm Hg·min/L)	.906	10	.252	
Recovery Systolic BP (mmHg)	.918	10	.338	
Recovery Diastolic BP (mmHg)	.886	10	.151	
Recovery HR ( beats/min)	.958	10	.760	
Recovery SV (ml)	.948	10	.648	
Recovery CO (ml/min)	.934	10	.493	
Recovery TPR (mm Hg·min/L)	.947	10	.630	

Kyes: BP: blood pressure; HR: heart rate; HGS, hand grips strength; MAP: mean arterial pressure; SV: stroke volume; CO: cardiac output; TPR: total peripheral resistance.

Table E3. Accelerometer measurements of free living physical activity following 3day supplementation with N, ND, and N+VC Interventions. P N+VC Sedentary activity 639.8±57.6 714.53±77.77  $729.66 \pm 74.70$ 0.25 time (mins)  $40.2 \pm 11.0$  $47.93\pm13.02$  $34.33 \pm 8.84$ Light activity 117.7±35.6  $125.76 \pm 35.18$  $110.66 \pm 32.42$ 0.16  $7.70\pm2.49$  $13.80 \pm 4.03$  $7.35\pm2.80$ time (mins)  $78.22 \pm 6.03$  $80.99 \pm 5.40$ Moderate activity  $79.60 \pm 5.77$ 0.33  $4.89 \pm 1.28$  $5.94 \pm 1.40$  $4.32 \pm 1.11$ time (mins) Vigorous activity  $14.34 \pm 4.25$  $14.58 \pm 4.13$  $13.57 \pm 4.01$ 0.03\*  $0.95 \pm .32$  $1.58 \pm .48$  $0.84 \pm .33$ time (mins) 0.28 **Sedentary** activity % Light activity % 0.12 0.57 Moderate activity % Vigorous 0.03\* activity %

Key: N, nitrate alone; ND, nitrate depleted; N+VC, nitrate with vitamin C. Values are reported as means  $\pm$  SEM. Repeated-measure ANOVA was used to evaluate differences between the three groups.




Figure E1. Flow chart showing recruitment, allocation to treatment and compliance to study.